Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
PURITAN MEDICAL
Bio-Rad Diabetes Division

Rapid Technology Identifies Cancer Gene Status

By Labmedica International staff writers
Posted on 05 Mar 2013
A fluorescence in situ hybridization (FISH) assay will reduce the turnaround time for cancer evaluation from two days to three and a half hours.

This technology will ease the waiting time and associated anxiety for the patient and allow physicians to more quickly initiate targeted cancer treatments.

Dako, an Agilent Technologies Company (Carpinteria, CA, USA) has introduced instant quality in situ hybridization (IQISH) technology in the United States of America. The HER2 IQFISH pharmDx test is a FISH assay, is the first product approved by the US Food and Drug Administration (Silver Spring, MD, USA) that uses the Dako IQISH technology, which is based on Dako's fast IQISH hybridization buffer chemistry.

The human epidermal growth factor receptor 2 (HER2) protein is encoded by gene called HER2, which promotes the growth of cells. In about one of every five breast cancers, the cancer cells make an excess of HER2 due to a HER2 gene mutation. The HER2 IQFISH pharmDx assay can support laboratories in identifying HER2 gene status with great accuracy and now, speed. HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. As they are also less responsive to hormone treatment, medical treatments that specifically target HER2, for example trastuzumab, are often considered.

The IQFISH technology is also nontoxic, as it replaces a hazardous formamide buffer with a safer ethylene carbonate, contributing to a healthier work environment in the pathology laboratory. Lars Holmkvist, the CEO of Dako, said, "Every second counts when waiting for test results that will indicate how to treat your cancer most effectively. Dako is extremely proud to get the FDA's approval to introduce this offering to our US customers."

Kenneth J. Bloom, MD, FCAP, chief medical officer, Clarient Diagnostic Services Inc (Aliso Viejo, CA, USA) said, "HER2 IQFISH pharmDx will provide more timely results, allowing us to incorporate FISH analysis into our routine workflow as easily as immunohistochemistry.” HER2 IQFISH pharmDx has been sold in Europe and countries working with CE labeling, the mark of compliance with relevant European regulations, since February 2012.

Related Links:

Dako
US Food and Drug Administration
Clarient Diagnostic Services Inc.



KARL HECHT GMBH & CO KG
ADVANCED INSTRUMENTS
DIASYS DIAGNOSTIC SYSTEMS
WATERS CORPORATION

Channels

Genetic Tests

view channel

Overexpression of X Chromosome Genes Is Biomarker for Female Mental Disorders

A recent paper suggested that elevated expression of the genes XIST (X-inactive specific transcript) and KDM5C (lysine-specific demethylase 5C) could be used as a biological marker for diagnosis of major affective disorders in a significantly large subset of female patients from the general population. Xist is an RNA... Read more

Immunology

view channel

Powerful Innovations in Diagnostics Unveiled at EuroMedLab 2015

New systems presented by Roche include a new standard for immunology testing, an integrated platform for hematology diagnostics, and a high-throughput analyzer to perform HbA1c tests for blood glucose management. Also, evidence was presented for a high-sensitivity cardiac troponin test to provide earlier and more accurate... Read more

Industry News

view channel

Hitachi High-Tech and QIAGEN Partner to Advance Diagnostics

Hitachi High-Technologies Corporation (Tokyo, Japan) and QIAGEN N.V. (Venlo, The Netherlands) have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing. Under terms of the agreement both companies will bring their unique strengths to the collaboration:... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.